Eyeworld Daily News

EW SHOW DAILY 22 Innovation and craftsmanship that helps you rise above. Haag-Streit vision spans more than 150 years. Our goal is simple: to develop ever more useful tools for the precise understanding of the human eye. At Haag-Streit, you will see the future clearly. 80O.787.5426 haag-streit-usa.com © 2016 Haag-Streit USA. All Rights Reserved. Visit us at ASCRS 2016 Booth #245 FAMOUS FOR SEEING WHAT OTHERS CAN'T. Octopus 600 Reliance FX920 LENSTAR APS Haag-Streit Surgical Hi-R NEO 900 Haag-Streit BQ 900 LED Haag-Streit ASCRS News Today Saturday, May 7, 2016 vidually. Our system provides a way for surgeons to evaluate multiple risk factors simultaneously using a simple chart." Dr. Stulting served as presi- dent of ASCRS from 2010–2011, in addition to holding various lead- ership positions in other notable organizations, such as the American Academy of Ophthalmology, the Eye Bank Association of America, and the Georgia Eye Bank. He was edi- tor-in-chief of Cornea for 10 years; he has and continues to serve on several editorial boards for medical magazines and peer-reviewed jour- nals, including EyeWorld, the Journal of Cataract & Refractive Surgery, and the Journal of Refractive Surgery. Dr. Stulting's ultimate goal is to reduce the risk of refractive surgery and improve outcomes. "We've had spectacular out- comes with the recent topography- guided LASIK clinical trial of the WaveLight laser from Alcon [Fort Worth, Texas]. We found that the majority of patients after treatment had visual acuities without cor- rection that were at least as good as what they had before surgery with correction. They also noticed an improvement in the quality of vision—a reduction in glare, ha- los, and driving difficulties. We're moving from an era when we had to warn patients that there was a compromise—that in order to be free from glasses they would have to accept some of these visual aberra- tions and visual complaints—to a day when we can offer patients a method of visual correction that's even better than their glasses or contact lenses. This new technology may also be applicable to patients with keratoconus and post-LASIK ectasia following corneal collagen crosslinking," he said, adding that this will be a topic included in his Binkhorst Lecture. Dr. Stulting has been perform- ing corneal collagen crosslinking ex- perimentally for more than 8 years and has seen the technology evolve to become much safer. He thinks that it will eventually become the standard treatment for keratoconus as soon as it is diagnosed. "Appro- priately applied, corneal collagen crosslinking could eliminate kera- toconus as a cause of visual loss in this country," he said. "It has been a real privilege to be involved in its development and to be able to offer it to my patients." EW Editors' note: Dr. Stulting has financial interests with Alcon. might increase the risk of ectasia after LASIK. "We developed a method of determining the risk of ectasia for patients who were undergoing LASIK and implemented it to reduce the incidence of ectasia in our practice, and it has been adapted by others since that time," he said. "Many people recognized the same risk factors that we identified, but they didn't apply them in a consistent way, nor did they apply them simultaneously. One of the great benefits of the system that we developed is that it recognizes multi- ple risk factors, weighs each of them, and evaluates them simultaneously in a simple, easy-to-use format," he said. "We know that refractive error, age, topography, corneal thickness, and residual stromal bed thickness are all risk factors. If there is a slight- ly abnormal topography in a patient who is a little bit younger than average with a slightly thinner than normal cornea, there may be a high risk of ectasia, even though none of these factors would be red flags indi- continued from page 21

• Cover